TY - JOUR
AU - Wu, Xiaoke
AU - Yu, Kaijiang
AU - Wang, Yongchen
AU - Xu, Wanhai
AU - Ma, Hongli
AU - Hou, Yan
AU - Li, Yue
AU - Cai, Benzhi
AU - Zhu, Liying
AU - Zhang, Min
AU - Hu, Xiaoli
AU - Gao, Jingshu
AU - Wang, Yu
AU - Qin, Huichao
AU - Wang, Wenjie
AU - Zhao, Mingyan
AU - Wu, Xia
AU - Zhang, Yong
AU - Li, Lu
AU - Li, Kang
AU - Du, Zhimin
AU - Mol, Ben Willem
AU - Yang, Baofeng
PY - 2021
DA - April
TI - Efficacy and safety of triazavirin therapy for coronavirus disease 2019: A pilot randomized controlled trial
JO - Engineering
EP - 1191
VL - 6
IS - 10
DO - https://doi.org/10.1016/j.eng.2020.08.011
AB - No therapeutics have been proven effective yet for the treatment of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To assess the efficacy and safety of Triazavirin therapy for COVID-19, we conducted a randomized, double-blinded controlled trial involving hospitalized adult patients with COVID-19. Participants were enrolled from ten sites, and were randomized into two arms of the study with a ratio of 1:1. Patients were treated with Triazavirin 250 mg versus a placebo three or four times a day for 7 d. The primary outcome was set as the time to clinical improvement, defined as normalization of body temperature, respiratory rate, oxygen saturation, cough, and absorption of pulmonary infection by chest computed tomography (CT) until 28 d after randomization. Secondary outcomes included individual components of the primary outcome, the mean time and proportion of inflammatory absorption in the lung, and the conversion rate to a repeated negative SARS-CoV-2 nucleic acid test of throat swab sampling. Concomitant therapeutic treatments, adverse events, and serious adverse events were recorded. Our study was halted after the recruitment of 52 patients, since the number of new infections in the participating hospitals decreased greatly. We randomized 52 patients for treatment with Triazavirin (n= 26) or a placebo (n= 26). We found no differences in the time to clinical improvement (median, 7 d versus 12 d; risk ratio (RR), 2.0; 95% confidence interval (CI), 0.7–5.6;p= 0.2), with clinical improvement occurring in ten patients in the Triazavirin group and six patients in the placebo group (38.5% versus 23.1%; RR, 2.1; 95% CI, 0.6–7.0;p= 0.2). All components of the primary outcome normalized within 28 d, with the exception of absorption of pulmonary infection (Triazavirin 50.0%, placebo 26.1%). Patients in the Triazavirin group used less frequent concomitant therapies for respiratory, cardiac, renal, hepatic, or coagulation supports. Although no statistically significant evidence was found to indicate that Triazavirin benefits COVID-19 patients, our observations indicated possible benefits from its use to treat COVID-19 due to its antiviral effects. Further study is required for confirmation.
PB - Elsevier
UR - https://aura.abdn.ac.uk/handle/2164/16182
KW - Coronavirus (COVID-19)
ER